latam

Regístrate
Invertir conlleva riesgos y puede no ser adecuado para todos los inversores.

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

Inicio・Lista de Acciones・Mirati Therapeutics Inc
Search

Mirati Therapeutics Inc

Abierto

Sector Salud

0

Neutral

Precios actualizados 1 ene 1970, 00:00 UTC

ComprarVender

Resumen

Variación precio

24h

Actual

Mínimo

Máximo

Métricas clave

By Trading Economics

Ingresos

-162M

Ventas

16M

BPA

-2.49

Margen de beneficio

-987.22

EBITDA

-171M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 meses

-0.05 downside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-41M

4.1B

Apertura anterior

0

Cierre anterior

0

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

56 / 365 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

58.54 / 58.9 Soporte y Resistencia

Mirati Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

9 oct 2023, 14:15 UTC

Adquisiciones, fusiones, absorciones

Trending: Bristol Myers Squibb Buying Mirati Therapeutics

DJ

Leer

9 oct 2023, 10:11 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

Mirati Shares Slip Premarket on Bristol Myers Takeover

DJ

Leer

6 oct 2023, 06:41 UTC

Adquisiciones, fusiones, absorciones

Sanofi Considering Acquisition of Mirati Therapeutics, Bloomberg Reports

DJ

Leer

23 ene 2024, 13:30 UTC

Adquisiciones, fusiones, absorciones

Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics

DJ

Leer

9 oct 2023, 15:25 UTC

Adquisiciones, fusiones, absorciones

Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Bid -- IBD

DJ

Leer

9 oct 2023, 13:56 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Bristol Still Has Flexibility After Mirati Deal -- Market Talk

DJ

Leer

9 oct 2023, 13:52 UTC

Adquisiciones, fusiones, absorciones

Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Bid -- IBD

DJ

Leer

9 oct 2023, 13:40 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Guggenheim: Bristol-Mirati Deal Plugs Bristol's Holes -- Market Talk

DJ

Leer

9 oct 2023, 11:18 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Bristol Hedges Mirati Bet With MRTX1719 CVRs -- Market Talk

DJ

Leer

9 oct 2023, 09:27 UTC

Adquisiciones, fusiones, absorciones

Mirati Stock Falls as Bristol Myers to Buy Oncology Developer for Up to $5.8 Billion -- Barrons.com

DJ

Leer

8 oct 2023, 22:12 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 Billion -- WSJ

DJ

Leer

8 oct 2023, 21:34 UTC

Adquisiciones, fusiones, absorciones

Bristol Myers Squibb to Finance Transaction With Cash and Debt

DJ

Leer

8 oct 2023, 21:34 UTC

Adquisiciones, fusiones, absorciones

Bristol Myers Squibb: Transaction Will Be EPS Dilutive by $0.12/Share in First 12 Months

DJ

Leer

8 oct 2023, 21:29 UTC

Adquisiciones, fusiones, absorciones

Bristol Myers Squibb: Non-Tradeable Rights Add $1 Bln of Value Opportunity

DJ

Leer

8 oct 2023, 21:29 UTC

Adquisiciones, fusiones, absorciones

Bristol Myers Squibb: Mirati Board Unanimously Approves Transaction

DJ

Leer

8 oct 2023, 21:28 UTC

Adquisiciones, fusiones, absorciones

Bristol Myers Squibb Will Also Pay One Contingent Value Right Per Share

DJ

Leer

8 oct 2023, 21:27 UTC

Adquisiciones, fusiones, absorciones

Bristol Myers Squibb: Acquisition Values Mirati's Equity at $4.8 Bln

DJ

Leer

8 oct 2023, 21:26 UTC

Adquisiciones, fusiones, absorciones

Bristol Myers Squibb to Acquire Mirati for $58/Share in Cash

DJ

Leer

8 oct 2023, 21:26 UTC

Adquisiciones, fusiones, absorciones

Bristol-Myers Squibb: Transaction to Be Dilutive to Co's Non-GAAP EPS by About 35c/Shr in First 12 Mos After Transaction Closes >BMY

DJ

Leer

8 oct 2023, 21:25 UTC

Adquisiciones, fusiones, absorciones

Bristol-Myers Squibb To Acquire Mirati for $58 Per Shr in Cash, for a Total Equity Value of $4.8B >BMY MRTX

DJ

Leer

Comparación entre iguales

Cambio de precio

Mirati Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

-0.05% caída

Estimación a 12 meses

Media 58.67 USD  -0.05%

Máximo 59 USD

Mínimo 58 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Mirati Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

5 ratings

0

Comprar

5

Mantener

0

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Mirati Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

58.54 / 58.9Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Medio plazo

Bullish Evidence

All events are bullish.

Largo Plazo

Bullish Evidence

Bullish events outweigh bearish events.

Sentimiento

By Acuity

56 / 365 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

EBITDA

Beneficio operativo

$

Acerca de Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.

Otras acciones del sector

LLY

Eli Lilly and Co.

922.4

↓-0.08%

UNH

UnitedHealth Group Inc

589.22

↓-0.85%

NVO

Novo Nordisk A-S

137.37

↑ +0.29%

JNJ

Johnson and Johnson

166.55

↑ +0.63%

ABBV

AbbVie Inc

195.28

↑ +0.62%